News and Press
Syntaxin Appoints CMO and Head of Cell Biology
News
FEB
2008
Syntaxin expands its team with the appointment of Chief Medical Officer and Head of Cell Biology
Oxford, UK, 12 February 2008: Syntaxin Ltd (“Syntaxin” or “the Company”), a biopharmaceutical company developing novel biologic drugs that control cell secretion, today announces that it has appointed Richard Jones, MD as Chief Medical Officer and Dr Nicola Thompson as Head of Cell Biology.
Richard Jones has over 25 years of global pharmaceutical industry experience with an extensive background in all stages of drug development and regulatory affairs. He has held senior development roles at Johnson & Johnson and Hoffman La Roche and most recently served as Senior Vice President, Experimental Medicine, Clinical and Regulatory Affairs at Aspreva Pharmaceuticals.
Prior to joining Syntaxin, Nicola Thompson worked at GSK as Head of Allergic Mechanism and Target Discovery. Nicola has 20 years of experience in the pharmaceutical industry and has a successful track record in drug discovery, primarily focused on respiratory and inflammatory diseases. Nicola was Allergy Champion for GSK’s respiratory disease area and a core member of the senior management Asthma/Rhinitis Disease Expert Team.
Patrick Doyle, CEO of Syntaxin, said: “Richard and Nicola are both highly respected figures in the pharmaceutical industry and I am delighted to welcome them to Syntaxin. Having recently completed a Series B fundraising of £16m, we are well positioned to broaden our expertise in respiratory, endocrine and gastric disorders, a key focus of our novel proprietary pipeline. Richard and Nicola will both provide a significant contribution to our efforts in building an innovative biopharmaceutical company addressing unmet medical needs in chronic diseases.”
--ends--
Enquiries:
Syntaxin Ltd Tel: +44 (0)1235 552112
Patrick Doyle, Chief Executive
Financial Dynamics Tel: +44 (0)20 7831 3113
Julia Phillips
Emma Thompson
About Syntaxin (www.syntaxin.com)
Syntaxin Ltd is a biopharmaceutical company focusing on the discovery and development of new medicines derived from bacterial toxins to treat chronic diseases. The Company was created in 2005 as a spin out from the UK Health Protection Agency, with funding from Abingworth Management Ltd.